The same combination treatment also showed to be very efficacious in four further PDX models (Fig. 6b–e); ovarian models CTG-703 (ATM WT, BRCA1 mutant, CHEK2 amplified, TP53 mutant, RB1 deleted, XRCC3 deleted) and OV2022 (ATM WT, TP53 mutant), NSCLC model CTG-0828 (ATM mutant, FANCA mutant, NBN mutant) and H&N model CTG-0149 (ATM WT, TP53 mutant), achieving 60–70% tumour regression in the first three models and 90% TGI in the fourth model. Here, ATM is linked to non-small cell lung carcinoma.